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Abstract
Background
While the importance of the Th2 cytokine IL-13 as a central mediator of airway hyperreactiv-
ity (AHR) has been described in allergic protein-induced asthma, this has never been inves-
tigated in chemical-induced asthma.
Objective
We examined the importance of IL-13 in a mouse model of chemical-induced AHR, using
toluene-2,4-diisocyanate (TDI).
Methods
In a first set-up, wild type (WT) and IL-13 knockout (KO) C57Bl/6 mice were dermally treated
on days 1 and 8 with 1% TDI or vehicle (acetone/olive oil) on both ears. On day 15, mice
received an intranasal instillation with 0.1% TDI or vehicle. In a second set-up, WT mice
sensitized with 1% TDI or vehicle, received i.v. either anti-IL-13 or control antibody prior to
the intranasal challenge.
Results
TDI-sensitized and TDI-challenged WT mice showed AHR to methacholine, in contrast to
TDI-sensitized and TDI-challenged IL-13 KO mice, which also showed lower levels of total
serum IgE. TDI-sensitized and TDI-challenged IL-13 KO mice had lower numbers of T-cells
in the auricular lymph nodes. TDI-treated WT mice, receiving anti-IL-13, showed no AHR, in
contrast to those receiving control antibody, despite increased levels of IgE. Anti-IL-13 treat-
ment in TDI-treated WT mice resulted in lower levels of serum IL-13, but did not induce
changes in T- and B-cell numbers, and in the cytokine production profile.
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Conclusion and clinical relevance
We conclude that IL-13 plays a critical role in the effector phase of chemical-induced,
immune-mediated AHR. This implicates that anti-IL-13 treatment could have a beneficial
effect in patients with this asthma phenotype.
Introduction
Asthma is a chronic airway disease, that encompasses many diverse phenotypes [1]. The most
common and well-characterized phenotype is allergic (atopic) asthma [2]. This form of asthma
is associated with T-helper (Th) 2-biased immune responses, resulting in the formation of
allergen-specific IgE antibodies and release of Th2 cytokines [3,4]. Abundant evidence from
both human and animal studies has shown that the Th2 cytokine IL-13 plays a central role in
directing the immune response to an allergic asthma phenotype [5]. On its own, IL-13 is suffi-
cient to induce some of the main characteristics of allergic asthma, i.e. airway hyperreactivity
(AHR), airway inflammation via eosinophil recruitment, mucus production by airway epithe-
lial cells and sub-epithelial fibrosis [5,6].
The prototypical type 2 cytokine, IL-13 is mainly produced by Th2 cells and innate lym-
phoid 2 cells, but can also be produced by many other immune cells, including Th1 cells, natu-
ral killer T-cells, mast cells, basophils and eosinophils [7,8]. The immunoregulatory function
of IL-13 is mediated by its binding to a heterodimeric receptor complex, comprising IL-4
receptor α and IL-13 receptor α1, resulting in the activation of the signal transducer and acti-
vator of transcription (STAT)6 pathway, or by binding to an IL-13 specific chain, IL-13 recep-
tor α2 [9].
The importance of IL-13 in regulating the pathogenesis of asthma in humans was demon-
strated by genome-wide association studies, showing an association between polymorphisms
of IL-13 and its receptor and asthma susceptibility [2]. Patients with mild atopic asthma show
an increased expression of IL-13 in bronchoalveolar lavage (BAL) fluid and cells compared to
control subjects [2]. In patients with this asthma phenotype, lebrikizumab, a monoclonal anti-
body to IL-13 is effective in improving lung function [10].
In murine models of allergic asthma, using ovalbumin as a classical protein allergen, IL-13
has been implicated as an inducer of AHR [11,12]. This was proven by using mice deficient in
IL-13 and wild type mice treated with anti-IL-13 monoclonal antibodies. Both set-ups resulted
in a reduced AHR in response to an ovalbumin challenge [8,13,14]. In addition, it has been
shown that AHR is lowered in STAT6 deficient mice [15].
The importance of IL-13 in classic allergic asthma has thus been identified in both human
and animal studies. However, many subtypes of asthma are distinct from ‘classic’ asthma, in
which inflammation is mainly characterized by eosinophils. One of these subtypes is paucigra-
nulocytic asthma, representing a substantial fraction of all asthma cases, and which can be
induced by reactive chemicals [16,17]. In addition, up to 50% of all asthma cases are not attrib-
utable to atopy [18].
In mouse models of asthma induced by diisocyanates, a group of known chemical asthmo-
gens, it has been shown that both Th2 and Th1 cytokines, including IL-13, IL-4 and IFN-γ, are
associated with the development of asthma features. Depending on the mouse strain used and
the airway challenge technique (aerosol, intranasal or oropharyngeal), an influx of lympho-
cytes, eosinophils and neutrophils into the lungs was accompanying airway hyperreactivity
[19–21]. Yet, in a recently developed mouse model of non-atopic paucigranulocytic asthma,
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PLOS ONE | https://doi.org/10.1371/journal.pone.0180690 July 13, 2017 2 / 12
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
with increased serum IL-13 levels, the role of IL-13 remains largely unknown. To address this,
we have used this validated mouse model of chemical-induced immune-mediated paucigranu-
locytic asthma, using TDI [22].
Methods
Reagents
Toluene-2,4-diisocyanate (TDI) (98%; Fluka, CAS 584-84-9), acetyl-β-methylcholine (metha-
choline) and acetone were obtained from Sigma-Aldrich (Bornem, Belgium). Pentobarbital
(Nembutal1) was obtained from Sanofi Sante´ Animale (CEVA, Brussels, Belgium). Anti-
mouse IL-13 antibody (262A-5-1) and mouse IgG1 anti-human gp120 were kindly provided
by Genentech (San Francisco, California, USA). The vehicle (acetone/olive oil, AOO), used to
dissolve TDI consisted of a mixture of 2 volumes of acetone and 3 volumes of olive oil (Selec-
cio´n de Almazara, Carbonell, Madrid, Spain) for both the dermal sensitization and the intrana-
sal challenge. Concentrations of TDI are given as percent (v/v) in AOO.
Mice
Male wild type C57Bl/6 mice (6–8 weeks old) were obtained from Harlan (Horst, The Nether-
lands). IL-13 deficient mice on a C57Bl/6 background (8–10 weeks old) were kindly provided
by Prof. Tomoaki Hoshino. All mice were housed in filter top cages in a conventional animal
house with 12 h dark/light cycles, and they received lightly acidified water and pelleted food ad
libitum.
Experimental protocols of mouse experiments
As previously described, our model of chemical-induced asthma is based on prior systemic
sensitization, induced by dermal applications of the test chemical, followed by an airway chal-
lenge. Non-specific airway hyperreactivity to methacholine, lung inflammation and immuno-
logic responses are assessed one day later [22].
This protocol was applied to both wild type (WT) and IL-13 knock-out (KO) mice. On days
1 and 8, mice were dermally treated with 1% of toluene-2,4-diisocyanate (TDI) or vehicle
(acetone/olive oil, AOO, ratio 2:3) on the dorsum of both ears (20 μL/ear). On day 15, mice
received an intranasal instillation of 30 μL of 0.1% TDI (challenge) or vehicle (AOO, ratio 2:3).
Mice were sacrificed 24 h after the last challenge. Experimental treatment groups are referred
to as AOO/AOO, AOO/TDI and TDI/TDI. The first symbol identifies the agent used for der-
mal applications on days 1 and 8 (sensitization), whereas the second symbol identifies the
agent administered via intranasal instillation on day 15 (challenge). Experiments with the
IL-13 KO mice were performed over a two-month period, during which we included mice
depending on the availability of mice in successive litters. With each new litter, the available
mice were distributed over the three treatment groups, with an aim to include six mice per
group. The last mouse of the AOO/TDI groups did not survive the intranasal challenge and we
decided not to include another mouse (n = 5). Some extra mice were sensitized with TDI and
following a successful challenge included in the study. Therefore, the TDI/TDI groups has an
n of 8.
The same sensitization protocol (treatment on days 1 and 8) was used to test if the specific
anti-IL-13 antibody, 262A-5-1 influences the effector phase: thus, on days 13, 14 and 15,
mice received either 2.5 mg/mL of mouse IgG1 anti-mouse IL-13 antibody, or mouse IgG1
anti-human gp120, used as control antibody, by intravenous (i.v.) injection (100 μL) (8).
On day 15, 1 h after the last i.v. injection, mice received an intranasal challenge with TDI.
IL-13 in chemical-induced airway hyperreactivity
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Experimental groups are represented by three abbreviations: AOO/gp120/AOO, AOO/anti-
IL-13/AOO, AOO/gp120/TDI, AOO/anti-IL-13/TDI, TDI/gp120/TDI and TDI/anti-IL-13/
TDI. The first abbreviation identifies the agent used for sensitization, the second identifies the
antibody that was injected i.v., and the third identifies the agent used for the airway challenge.
All treatment groups contain eight mice. The analysis were spread-out over six experimental
days, with each day two mice of each group.
Non-specific airway hyperreactivity measurements
Twenty-four hours after the challenge, airway reactivity to methacholine was measured using a
forced oscillation technique (flexiVent 7, SCIREQ, Montreal, Canada), as described previously
[23]. Mice were anaesthetized by an intraperitoneal (i.p.) injection of pentobarbital (70 mg/kg
body weight, Nembutal1, Sanofi Sante´ Animale, CEVA, Brussels, Belgium). The trachea was
exposed and a 19-gauge metal needle was inserted. Mice were quasi-sinusoidally ventilated
with a tidal volume of 10 mL/kg at a frequency of 150 breaths/min and a positive end-expira-
tory pressure of 3 cm H2O, to mimic the characteristics of spontaneous breathing. Airway
resistance (Rn) was measured using the ‘quick-prime 3’ protocol, which induces oscillations of
1 to 20.5 Hz during 3 seconds. After baseline measurements, each mouse was exposed to a
methacholine aerosol, generated with an in-line nebulizer and administered at increasing con-
centrations (0, 1.25, 2.5, 5, 10, 20 mg/mL), each during 5 seconds. For each mouse, Rn was
plotted against methacholine concentration and the area under the curve (AUC) was calcu-
lated to obtain a single measure of AHR and to perform the statistical analysis.
Serum IgE
After measuring airway hyperreactivity to methacholine, mice were sacrificed. Blood was
taken from the retro-orbital plexus, centrifuged (14000 g, 4˚C, 10 min) and serum samples
were stored at −80˚C. The OptEIATM mouse IgE set from Pharmingen (BD Biosciences, Erem-
bodegem, Belgium) was used to measure total serum IgE (diluted 1/70).
IL-13 levels in serum and lung tissue homogenates
The Quantikine mouse IL-13 ELISA from R&D systems (Abingdon, UK) was used to measure
IL-13 levels in serum and lung tissue homogenates. A part of the left lung was snap-frozen
in liquid nitrogen and homogenized in a 5% BSA solution, using an Ultra-Turrax T25 (Ika
Works, Staufen, Germany). Afterwards, homogenates were centrifuged at 4˚C (1200 g, 10
min) and the supernatant was stored at −80˚C. The ELISA was performed according to the
manufacturer’s instructions, using undiluted serum samples or lung tissue homogenates. The
detection limit was 1.5 pg/mL.
Bronchoalveolar lavage (BAL)
The lungs were lavaged three times with 0.7 mL sterile saline (0.9% NaCl) in situ, and the re-
covered fluid was pooled. Cells were counted using a Bu¨rker hemocytometer (total cell count)
and the bronchoalveolar lavage (BAL) fluid was centrifuged (1000 g, 10 min). The supernatant
was frozen (-80˚C) until further analyses. For differential cell counts, 250 μL of the resus-
pended cells (100,000 cells/mL) were spun (300 g, 6 min) (Cytospin 3, Shandon, TechGen, Zel-
lik, Belgium) onto microscope slides, air-dried and stained (Diff-Quik1 method, Medical
Diagnostics, Du¨dingen, Germany). For each sample, 200 cells were counted to determine the
number of macrophages, eosinophils, neutrophils and lymphocytes.
IL-13 in chemical-induced airway hyperreactivity
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Lymph node analysis
Retro-auricular lymph nodes, obtained from the same mice were pooled and kept on ice in
RPMI-1640 (Invitrogen, Merelbeke, Belgium). Cell suspensions were obtained by pressing the
lymph nodes through a cell strainer (100 μm) (BD Bioscience, Erembodegem, Belgium) and
rinsing with 10 mL tissue culture medium (RPMI-1640). After centrifugation (1000 g, 10
min), cells were counted using a Bu¨rker hemocytometer and resuspended (107 cells/mL) in
complete tissue culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum, 10 mg/mL streptomycin/penicillin). Five-hundred thousand cells were stained
with anti-CD3+ (APC), anti-CD4+ (APC-Cy7), anti-CD8+ (PerCP-Cy5.5) and anti-CD25+
(PE), or received a single staining with anti-CD19+ (PE) labeled antibodies, according to stan-
dard procedures (BD Biosciences, Erembodegem, Belgium). Percentages of labeled cells were
determined by performing flow cytometry (Facsarray, BD Biosciences, Erembodegem, Bel-
gium) on at least 105 cells.
Cells were seeded into 48-well culture plates at a density of 106 cells/mL and incubated in
complete RPMI-1640 medium for 42 h with 2.5 μg/mL of concanavalin A (ConA) (Sigma–
Aldrich, Bornem, Belgium). Cell suspensions were then centrifuged (1000 g, 10 min) and
supernatant was stored at −80˚C. Levels of IL-4, IL-10, IL-13 and interferon gamma (IFN-γ)
were measured in undiluted supernatant, via Cytometric Bead Array and analyzed with the
FCAP Array Software (BD Biosciences, Erembodegem, Belgium) on the LSR Fortessa (BD Bio-
sciences, Erembodegem, Belgium). The detection limits for IL-4, IL-10, IL-13 and IFN-γ were
0.3 pg/mL, 9.6 pg/mL, 2.4 pg/mL and 0.5 pg/mL, respectively.
Data analyses
Dose-response curves (AHR) were analyzed using two-way parametric ANOVA, followed by a
Bonferroni multiple comparison post hoc test. For all other data, normality of distribution was
assessed by the Kolmogorov-Smirnov test. This data is presented as means with standard devi-
ation (SD), and were analyzed using one-way parametric ANOVA, followed by a Bonferroni
multiple comparison post hoc test (Graph Pad Prism 5. Graphpad Software Inc, San Diego,
USA). A level of p< 0.05 (two-tailed) was considered to be significant.
Study approval
All experimental procedures performed in mice were approved by the local Ethical Committee
for animal experiments (P166-2012).
Results
Airway and immune responses in IL-13 KO mice
To examine the role of IL-13 in the development of sensitizer-induced AHR, responses to
methacholine were measured in IL-13 KO mice sensitized and challenged with TDI and com-
pared to those of similarly treated WT mice. TDI-sensitized and TDI-challenged WT mice
showed AHR, while this was not the case in IL-13 KO mice. Airway resistance (Rn) to metha-
choline (5–20 mg/mL) in TDI-treated IL-13 KO mice did not differ from control IL-13 KO
mice, indicating that they were responsive to methacholine (Fig 1A and 1B). Cellular airway
inflammation was absent in the BAL fluid of both WT and IL-13 KO mice, confirming the
paucigranulocytic phenotype of this model of chemical-induced asthma [22] (S1 Table).
Immune sensitization to TDI was investigated by assessing total serum IgE levels, IL-13 lev-
els in serum and lung homogenates, and by assessing the lymph node subpopulations of the
auricular lymph nodes, i.e. the draining site of sensitization, and the associated ex vivo cytokine
IL-13 in chemical-induced airway hyperreactivity
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Fig 1. Airway and immune responses in IL-13 KO mice. (A) Dose-response curves of Rn to methacholine (0–20 mg/
mL). (B) Individual values and group means of the corresponding area under the curve (AUC) of airway hyperreactivity.
(C) Total serum immunoglobulin E (IgE) and (D) IL-13 levels. (E) Lymphocyte subpopulations from auricular lymph
IL-13 in chemical-induced airway hyperreactivity
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release. WT mice sensitized and challenged with TDI showed significantly increased levels of
total serum IgE and serum IL-13, compared to controls, whereas IL-13 KO mice sensitized and
challenged with TDI did not show detectable levels of serum IL-13 (Fig 1C and 1D). The TDI
treated IL-13 KO mice still showed significantly higher total serum IgE levels, yet, lower then
TDI treated WT mice. No detectable levels of IL-13 were found in lung homogenates of both
WT and IL-13 KO mice. IL-13 KO mice had similar lymphocyte subpopulations in the auricu-
lar lymph nodes, draining the site of sensitization, compared to WT mice. IL-13 KO mice sen-
sitized and challenged with TDI showed a significant increase in total number of CD3+ T-cells,
CD4+ T-helper (Th)-cells, CD25+ activated and regulatory T (Treg)-cells, CD8+ cytotoxic T
(Tc)-cells and CD19+ B-cells (Fig 1E). However, compared to WT mice, total numbers of
CD3+ T-cells, CD4+ Th-cells and CD8+ Tc-cells were significantly lower in IL-13 KO mice. In
WT mice, this increase in lymphocyte numbers was accompanied by an increased release of
Th2 (IL-13, IL-10) and Th1 (IFN-γ) cytokines, after in vitro stimulation of these lymphocytes
with concanavalin A (ConA) (Fig 1F, 1G and 1H). As expected, IL-13 KO mice showed no
release of IL-13, yet releases of both IFN-γ and IL-10 in TDI-sensitized and challenged IL-13
KO mice were significantly higher compared to the control treated IL-13 KO mice and were
not different from the WT mice receiving similar treatment (Fig 1F).
Airway and immune responses in anti-IL-13 treated WT mice
WT mice sensitized and challenged with TDI that received i.v. injections with anti-IL-13 did
not develop AHR, in contrast to those that had been treated with the control antibody, gp120
(Fig 2A and 2B). Anti-IL-13 treatment significantly decreased Rn at methacholine doses from
5 to 20 mg/mL in mice sensitized and challenged with TDI, compared to control antibody
treatment. Again, these mice did not show any inflammatory cells in the BAL fluid (S1 Table).
Total serum IgE levels were significantly increased in WT mice sensitized and challenged
with TDI, treated with anti-IL-13 antibody, compared to controls (Fig 2C), although lower
compared to those treated with the control antibody. Serum IL-13 levels remained at control
levels in WT mice sensitized and challenged with TDI, treated with anti-IL-13 antibody, and
were significantly lower than those treated with control antibody (Fig 2D). Lung homogenates
of WT mice treated with anti-IL-13 or control antibody showed no detectable levels of IL-13.
Lymphocyte subpopulations in the auricular lymph nodes, site of sensitization, were not
altered by anti-IL-13 treatment. Total numbers of CD3+ T-cells, CD4+ T-helper (Th)-cells, CD25+
activated and regulatory T-cells, CD8+ cytotoxic T (Tc) cells and CD19+ B-cells were significantly
increased in TDI-sensitized and TDI-challenged mice, treated with either anti-IL-13 or control
antibody, in comparison to the corresponding controls (Fig 2E). Total number of CD8+ Tc-cells
was, however, significantly lower in mice sensitized and challenged with TDI, treated with anti-
IL-13, compared to those treated with control antibody. The levels of ex vivo release of IL-13 in
the supernatants of ConA-stimulated lymphocytes of TDI-sensitized and challenged mice WT
mice, treated with IL-13 showed a higher trend, but was not significantly different from its
untreated control (Fig 2F). For ex vivo release of IFN-γ and IL-10, significant increased levels were
measured in the supernatant of lymphocytes from TDI-sensitized and challenged mice for both
the gp120 control treated, as the anti-IL-13 treated group. (Fig 2G and 2H).
nodes, stained with anti-CD3+, anti-CD3+CD4+, anti-CD3+CD4+CD25+ and anti-CD3+CD8+ or with anti-CD19+.
Associated cytokine release of (F) IL-13, (G) IFN-γ and (H) IL-10. Data are presented as mean ± SD. * p < 0.05,
** p < 0.01 and *** p < 0.001 compared to own corresponding control group (WT AOO/AOO or IL-13 KO AOO/AOO
group). # p < 0.05, ## p < 0.01 and ### p < 0.001 compared to WT TDI/TDI group. N.D., non-detectable levels. n = 5–8
per group.
https://doi.org/10.1371/journal.pone.0180690.g001
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Fig 2. Airway and immune responses in anti-IL-13 treated WT mice. (A) Dose-response curves of Rn to
methacholine (0–20 mg/mL). (B) Individual values and group means of corresponding area under the curve (AUC) of
airway hyperreactivity. (C) Total serum immunoglobulin E (IgE) and (D) IL-13 levels. (E) Lymphocyte subpopulations
IL-13 in chemical-induced airway hyperreactivity
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Discussion
We have demonstrated that IL-13 plays an important role in chemical-induced AHR. In con-
trast to WT mice, TDI-sensitized IL-13 KO mice failed to develop AHR 24 h after an airway
challenge with TDI. The lack of IL-13 was accompanied by lower total serum IgE levels, lower
numbers of T-cells, yet it did not affect the pro-inflammatory cytokines IFN-γ and IL-10. Still,
numbers of T-helper cells, cytotoxic T-cells and B-cells were significantly increased in IL-13
KO mice sensitized and challenged with TDI, compared to control IL-13 KO mice.
Since IL-13 plays a role in both the sensitization and the effector phase of of classical asthma
[6], the data obtained from the IL-13 KO mice, hence reduced T-lymphocyte numbers and
lower concentrations of systemic IgE, cannot fully explain the role of IL-13 in the effector
phase. Therefore, we investigated the effect of IL-13 neutralization in WT mice sensitized to
TDI, by using a specific anti-IL-13 antibody, following a treatment protocol effective in neu-
tralizing IL-13 and abrogating AHR, as shown by Hacha et al., using a model of ovalbumin-
induced asthma [8]. With this set-up, neutralizing IL-13 after the induction of TDI sensitiza-
tion, evidenced by significantly lower levels of serum IL-13, AHR was absent 24 h after an air-
way challenge with TDI, despite increased serum IgE levels, increased T-and B-cell numbers
and increased cytokine releases of IFN-γ and IL-10. This indicates that the lower concentration
of IgE and the decrease in T-cell numbers in IL-13 KO mice can be considered as an inherent
aspect of the gene-deficiency, thereby rendering IL-13 KO mice a less good tool to investigate
responses depending on two phases, i.e. sensitization and challenge.
The prophylactic treatment with anti-IL-13 provided evidence concerning the contribution
of IL-13 in the effector phase of the AHR response. Using a model of paucigranulocytic
asthma, we also demonstrate that AHR can be established without the presence of cellular
inflammation in the airways, as was already reported in a model of ovalbumin-induced asthma
[24]. So, as was shown previously that although IL-13 is able to promote the recruitment of
inflammatory cells into the airways, this is not necessary for the induction of AHR (12). This
concept was supported by demonstrating that IL-13-induced AHR is not affected in IL-5 and/
or eotaxin-deficient mice, and mice pretreated with a granulocyte inhibitor [25,26]. Moreover,
in line with our results, IL-13 is able to induce AHR, independently of T- and B-lymphocytes
[27].
In vitro studies, using airway smooth muscle cells of humans and rodents, have shown that
IL-13 increases the contractility of smooth muscle, via enhancing Ca2+ oscillations of airway
smooth muscle cells, thus implying a direct stimulatory effect of IL-13 on airway smooth cells
[28–30]. In addition, IL-13 was shown to increase the affinity of smooth muscle for acetylcho-
line released from cholinergic nerves [31]. More recently, by using transgenic mice selectively
expressing the IL-4 receptor α only in smooth muscle, Perkins et al. and Kirstein et al. showed
that smooth muscle activation by IL-13 is sufficient, but not essential, to induce AHR [32,33].
Indeed, IL-13 can also act on airway epithelial cells to induce AHR, as shown by the use of
transgenic mice expressing STAT6 only in airway epithelial cells [34]. Changes in the proper-
ties of airway epithelial cells, such as cell enlargement, increased permeability, increased rigid-
ity and mucus production, ultimately lead to airway narrowing and subsequent AHR
[32,34,35]. As such, it has been suggested that the effects of IL-13 on airway responsiveness
rely on the combined activation of both airway smooth muscle cells and airway epithelial cells
from auricular lymph nodes, stained with anti-CD3+, anti-CD3+CD4+, anti-CD3+CD4+CD25+ and anti-CD3+CD8+ or with
anti-CD19+. Associated cytokine release of (F) IL-13, (G) IFN-γ and (H) IL-10. Data are presented as mean ± SD.
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared to own corresponding control group (AOO/gp120/AOO or AOO/
anti-IL-13/AOO), # p < 0.05, ## p < 0.01 and ### p < 0.001 compared to WT TDI/gp120/TDI group. n = 8 per group.
https://doi.org/10.1371/journal.pone.0180690.g002
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[11]. Considering the fact that the IL-4 and IL-13 receptor is ubiquitously expressed, the effects
of IL-13 might also be induced via stimulation of cell types other than airway smooth muscle
and epithelial cells, such as macrophages, mast cells, dendritic cells. Activation of these cells
could in turn stimulate airway smooth muscle cells, epithelial cells or cholinergic nerves via
the production of inflammatory mediators [32,33].
In our model of chemical-induced asthma, we have previously established a role for T- and
B-lymphocytes, with the associated release of both Th1- and Th2-cytokines, including IL-13
[36–38]. TDI-treated ‘severe combined immunodeficiency’ mice lacking mature lymphocytes,
showed no respiratory, nor inflammatory responses [36]. Also, the adoptive transfer of small
amounts of lymphocytes from TDI-sensitized mice could passively sensitize naive mice and
induced asthma-like responses after a specific airway challenge, indicating the importance of
T- and B-lymphocytes [39,40]. More recently, we have also shown the involvement of neuro-
immune interactions, with a role for airway sensory nerves expressing the chemo-receptors
transient receptor potential (TRP)A1 and TRPV1, lymphocytes and mast cells in our model of
chemical-induced immune-mediated paucigranulocytic asthma [22]. Mice lacking either
TRPA1 (Trpa1-/-), TRPV1 (Trpv1-/-), mature lymphocytes (Rag2-/-) or mast cells (KitWsh/Wsh),
showed an abrogated AHR response. We concluded the existence of an interplay between
mast cells and airway sensory nerves. Stimulation of these nerves occurs via the direct activa-
tion of TRPA1 by the isocyanate moieties of TDI and via the indirect activation of TRPV1 by
immune-related inflammatory mediators [22]. Rehman et al. suggested a link between IL-13
and activation of neurogenic pathways, as IL-13 induced the expression of TRPV1 in the
murine lung [41]. Further research is necessary to explore the effects of IL-13 on the neuro-
genic system in developing AHR.
In conclusion, we found IL-13 to be critically involved in the development of chemical-
induced asthma, as shown here by using IL-13 KO mice, and more specifically in the effector
phase as confirmed by anti- IL-13 antibody treatment.
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